CoChat

Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance

Open access
Alves, Raquel, Gonçalves, Ana Cristina, Rutella, Sergio, Almeida, António M., De Las Rivas, Javier, Trougakos, Ioannis P., Sarmento Ribeiro, Ana Bela · 2021 · Cancers

The DOI matches its Crossref record; 311 of the 318 references it cites were found in a registry or an index.

Abstract

Resistance to targeted therapies is a complex and multifactorial process that culminates in the selection of a cancer clone with the ability to evade treatment. Chronic myeloid leukemia (CML) was the first malignancy recognized to be associated with a genetic alteration, the t(9;22)(q34;q11). This translocation originates the BCR-ABL1 fusion gene, encoding the cytoplasmic chimeric BCR-ABL1 protein that displays an abnormally high tyrosine kinase activity. Although the vast majority of patients with CML respond to Imatinib, a tyrosine kinase inhibitor (TKI), resistance might occur either de novo or during treatment. In CML, the TKI resistance mechanisms are usually subdivided into BCR-ABL1-dependent and independent mechanisms. Furthermore, patients’ compliance/adherence to therapy is critical to CML management. Techniques with enhanced sensitivity like NGS and dPCR, the use of artificial intelligence (AI) techniques, and the development of mathematical modeling and computational prediction methods could reveal the underlying mechanisms of drug resistance and facilitate the design of more effective treatment strategies for improving drug efficacy in CML patients. Here we review the molecular mechanisms and other factors involved in resistance to TKIs in CML and the new methodologies to access these mechanisms, and the therapeutic approaches to circumvent TKI resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13194820

Cites

311 of 311 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Molecular mechanisms of resistance to TKIs in CML. The molecular mechanisms responsible for TKI resistance in CML include: BCR-ABL1 mutations and BCR-ABL1 overexpression; alteration of DNA damage repair and genomic instability (increasing the additional chromosome abnormalities (ACAs) and point mutations); changes in drug transporters activity (e.g., increased efflux and decreased influx); activation of alternative signaling pathways (e.g., PI3K/AKT, JAK/STAT, and RAS/MAPK); changes in leukemia stem-cell metabolism and pathways (e.g., metabolic shift, Hypoxia/HIF-1α, and Alox5/β-catenin); epigenetic alterations (e.g., mutations on epigenetic regulating genes such as DNMT3A and/or increased methylation of p15 and EBF2 genes); altered expression of microRNAs (e.g., miR-17 and miR-203); changes in the microenvironment and immunological status (e.g., immunosuppressive bone marrow microenvironment (BMM) with increased MDSCs and Treg, plus exhausted T cells).
Figure 1 Molecular mechanisms of resistance to TKIs in CML. The molecular mechanisms responsible for TKI resistance in CML include: BCR-ABL1 mutations and BCR-ABL1 overexpression; alteration of DNA damage repair and genomic instability (increasing the additional chromosome abnormalities (ACAs) and point mutations); changes in drug transporters activity (e.g., increased efflux and decreased influx); activation of alternative signaling pathways (e.g., PI3K/AKT, JAK/STAT, and RAS/MAPK); changes in leukemia stem-cell metabolism and pathways (e.g., metabolic shift, Hypoxia/HIF-1α, and Alox5/β-catenin); epigenetic alterations (e.g., mutations on epigenetic regulating genes such as DNMT3A and/or increased methylation of p15 and EBF2 genes); altered expression of microRNAs (e.g., miR-17 and miR-203); changes in the microenvironment and immunological status (e.g., immunosuppressive bone marrow microenvironment (BMM) with increased MDSCs and Treg, plus exhausted T cells).CC BY · PubMed Central
Figure 2 Alternative to BCR-ABL1 signaling network. To evade BCR-ABL1 inhibition, CML cells activate alternative signaling pathways including RAS/MAPK, SRC, JAK/STAT, WNT/b-catenin, hedgehog, and PI3K/AKT. The transduction of oncogenic signals culminates with the activation of multiple downstream signaling pathways that enhance survival, inhibit of apoptosis, and alter cell adhesion and migration. A subset of these pathways and their constituent transcription factors (β-catenin, Gli, STAT5, MYC, FOXO3), serine/threonine-specific kinases (RAS/MAPKs, PI3K/AKT/mTOR), and apoptosis-related proteins (BAD, BCL-2, BCL-XL, survivin) are shown. It is important to note that this is a simplified diagram and that many more associations between BCR-ABL1 and signaling proteins have been reported.
Figure 2 Alternative to BCR-ABL1 signaling network. To evade BCR-ABL1 inhibition, CML cells activate alternative signaling pathways including RAS/MAPK, SRC, JAK/STAT, WNT/b-catenin, hedgehog, and PI3K/AKT. The transduction of oncogenic signals culminates with the activation of multiple downstream signaling pathways that enhance survival, inhibit of apoptosis, and alter cell adhesion and migration. A subset of these pathways and their constituent transcription factors (β-catenin, Gli, STAT5, MYC, FOXO3), serine/threonine-specific kinases (RAS/MAPKs, PI3K/AKT/mTOR), and apoptosis-related proteins (BAD, BCL-2, BCL-XL, survivin) are shown. It is important to note that this is a simplified diagram and that many more associations between BCR-ABL1 and signaling proteins have been reported.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 311 references

Cited by

See all 218

Metadata

Authors
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B.
Affiliations
  • Centro de Investigação em Meio Ambiente Genética e Oncobiologia (PT)
  • Nottingham Trent University (GB)
  • Hospital da Luz Lisboa, 1500-650 Lisbon, Portugal
  • Cancer Research Center (CiC-IBMCC, CSIC/USAL/IBSAL, Consejo Superior de Investigaciones Científicas (CSIC), University of Salamanca (USAL) and Instituto de Investigación Biomédica de Salamanca (IBSAL)), 37007 Salamanca, Spain
  • National and Kapodistrian University of Athens (GR)
  • Laboratory of Oncobiology and Hematology, University Clinic of Hematology, Faculty of Medicine (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal
Venue
Cancers
Publisher
MDPI AG
Published
2021-09-26
Volume
13
Issue
19
Pages
4820
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3204122798
Cited by
204
References
318
Citations by year
2026: 42 · 2025: 51 · 2024: 38 · 2023: 46 · 2022: 27
FWCI
4.86
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Nottingham Trent University's Institutional Repository (Nottingham Trent Repository) (acceptedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Estudo Geral (Universidad de Coimbra) (submittedVersion, cc-by)
Funders
  • Fundação para a Ciência e a Tecnologia (UIDB/04539/2020, UIDP/04539/2020)
  • Ministerio de Ciencia e Innovación (PI18/00591)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
chronic myeloid leukemia, tyrosine kinase inhibitors, imatinib, drug resistance, BCR-ABL fusion gene, medication adherence, next-generation sequencing, digital PCR, artificial intelligence, mathematical modeling, resistance mechanisms, treatment options

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. https://app.cochat.ai/papers/10.3390/cancers13194820
The paper
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021). Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers. https://doi.org/10.3390/cancers13194820

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.